Trv Gp Iii 13F annual report

Trv Gp Iii is an investment fund managing more than $18.2 billion ran by Kevin Gillis. There are currently 2 companies in Mr. Gillis’s portfolio. The largest investments include Decibel Therapeutics, Inc. and Pliant Therapeutics, together worth $18.2 billion.

$18.2 billion Assets Under Management (AUM)

As of 3rd August 2023, Trv Gp Iii’s top holding is 3,139,685 shares of Decibel Therapeutics, Inc. currently worth over $12.1 billion and making up 66.3% of the portfolio value. In addition, the fund holds 339,160 shares of Pliant Therapeutics worth $6.15 billion, whose value fell 42.7% in the past six months.

Currently, Trv Gp Iii's portfolio is worth at least $18.2 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Trv Gp Iii

The Trv Gp Iii office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Kevin Gillis serves as the Chief Operating Officer at Trv Gp Iii.

Recent trades

There are companies that Trv Gp Iii is getting rid of from its portfolio. Trv Gp Iii closed its position in Revolution Medicines Inc on 10th August 2023. It sold the previously owned 3,604,130 shares for $71.1 million. Kevin Gillis also disclosed a decreased stake in Pliant Therapeutics by 0.9%. This leaves the value of the investment at $6.15 billion and 339,160 shares.

One of the smallest hedge funds

The two most similar investment funds to Trv Gp Iii are Ayrton Capital and Freemont Capital Pte Ltd. They manage $18.2 billion and $18.2 billion respectively.

Kevin Gillis investment strategy

Trv Gp Iii’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 33.7% of the total portfolio value. The fund focuses on investments in the United States as 50.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $935 million.

The complete list of Trv Gp Iii trades based on 13F SEC filings

These positions were updated on August 10th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Decibel Therapeutics, Inc.	No change 3,139,685	$12,087,787,000	66.29%
Pliant Therapeutics, Inc.	91.17% 339,160	$6,145,579,000	33.71%
Revolution Medicines Inc	Closed 3,604,130	$71,073,000
Voyager Therapeutics Inc	Closed 5,428,933	$32,139,000
Fulcrum Therapeutics Inc	Closed 3,962,202	$32,054,000
Jounce Therapeutics Inc	Closed 1,148,780	$2,688,000
No transactions found
Showing first 500 out of 6 holdings